BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-10
216 industry Phase 2/3 trial readout(s) and 38 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-10 est. | P3 | Advenchen Laboratories, LLC | NCT02584478 Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Prima | Endometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Ce | unknown | 294 |
| 2024-10 est. | P2 | Techfields Inc | NCT02785120 A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes | Ischemic Stroke | suspended | 225 |
| 2024-10 est. | P3 | Philogen S.p.A. | NCT02938299 Neoadjuvant L19IL2/L19TNF- Pivotal Study | Malignant Melanoma | active not recruiting | 214 |
| 2024-10 est. | P1/P2 | Orca Therapeutics B.V. | NCT04097002 First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | Adenocarcinoma of the Prostate | unknown | 24 |
| 2024-10 est. | P1/P2 | NexImmune Inc. | NCT04284228 Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) | unknown | 22 |
| 2024-10 est. | P2 | Tracon Pharmaceuticals Inc. | NCT04480502 ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma | unknown | 207 |
| 2024-10 est. | P2 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | NCT04920617 DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma | recruiting | 102 |
| 2024-10 est. | P2 | RemeGen Co., Ltd. | NCT04965519 A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies | Gynecological Malignancy | unknown | 120 |
| 2024-10 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05145218 A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovaria | Recurrent Platinum-resistant Ovarian Cancer | unknown | 405 |
| 2024-10 est. | P1/P2 | Cyclacel Pharmaceuticals, Inc. | NCT05168904 A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | Leukemia; Myelodysplastic Syndrome(MDS) | suspended | 210 |
| 2024-10 est. | P2 | Wohlstand Pharmaceutical | NCT05465798 Beta-glucans for Hospitalised Patients With COVID-19 | COVID-19 | unknown | 60 |
| 2024-10 est. | P3 | Matinas BioPharma Nanotechnologies, Inc. MTNB | NCT05541107 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 | Cryptococcal Meningitis | unknown | 270 |
| 2024-10 est. | P2 | Emboline | NCT05684146 Protect the Head to Head Study | Embolism | unknown | 540 |
| 2024-10 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05718167 TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamo | Advanced Squamous Non-Small Cell Lung Carcinoma | unknown | 570 |
| 2024-10 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT06041035 A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | Solid Tumor | unknown | 115 |
| 2024-10 est. | P1/P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT06213363 A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough | Refractory Chronic Cough | unknown | 72 |
| 2024-10 est. | P1/P2 | Supergenics Life Science Sdn. Bhd. | NCT06231771 Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer | Diabetic Foot Ulcer | unknown | 22 |
| 2024-10 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06270225 A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. | Gout Arthritis | unknown | 157 |
| 2024-10-01 | P2/P3 | ImmunityBio, Inc. IBRX | NCT03022825 QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive H | Bladder Cancer | active not recruiting | 190 |
| 2024-10-01 | P3 | Celgene | NCT03440372 Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Crohn Disease | terminated | 625 |
| 2024-10-01 | P3 | Healios K.K. | NCT03545607 MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study | Ischemic Stroke | terminated | 206 |
| 2024-10-01 | P3 | AbbVie ABBV | NCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD) | Parkinson Disease | completed | 304 |
| 2024-10-01 | P2/P3 | Healios K.K. | NCT04367077 MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) | ARDS | terminated | 22 |
| 2024-10-01 est. | P2 | UBP Greater China (Shanghai) Co., Ltd | NCT04714060 UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals | Recurrent Genital Herpes | unknown | 44 |
| 2024-10-01 | P2 | Gilead Sciences GILD | NCT04827576 Study of Magrolimab in Patients With Solid Tumors | Solid Tumor | terminated | 106 |
| 2024-10-01 | P3 | H. Lundbeck A/S | NCT04921384 Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine | Migraine | completed | 981 |
| 2024-10-01 est. | P3 | Organ, Tissue, Regeneration, Repair and Replacement | NCT05528328 Post-surgical Scars After the Use of CACIPLIQ20 | Scars | unknown | 50 |
| 2024-10-01 | P3 | Biocad | NCT05726630 Clinical Study of Divozilimab in Patients With Systemic Scleroderma | Systemic Scleroderma | active not recruiting | 152 |
| 2024-10-01 | P3 | Colgate Palmolive CL | NCT06048627 Anti-gingivitis Mouthrinse | Gingivitis | completed | 90 |
| 2024-10-01 | P2 | Servier | NCT06081829 A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic | active not recruiting | 12 |
| 2024-10-02 | P1/P2 | AbbVie ABBV | NCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm | active not recruiting | 179 |
| 2024-10-02 | P1/P2 | Enterome | NCT04187404 A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | Adrenocortical Carcinoma; Pheochromocytoma; Paraganglioma | terminated | 70 |
| 2024-10-02 | P3 | Novartis Pharmaceuticals NVS | NCT04266301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as P | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic | terminated | 530 |
| 2024-10-02 | P2 | Gilead Sciences GILD | NCT04854499 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | terminated | 193 |
| 2024-10-02 | P3 | Cassava Sciences, Inc. | NCT04994483 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease | Alzheimer Disease | completed | 804 |
| 2024-10-02 est. | P3 | Novo Nordisk A/S NVO | NCT05444153 Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity | Diabetes Mellitus, Type 2 | withdrawn | |
| 2024-10-02 | P2 | Beckley Psytech Limited | NCT05674929 An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder | Alcohol Use Disorder | completed | 13 |
| 2024-10-02 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06176196 Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) | Painful Lumbosacral Radiculopathy | completed | 218 |
| 2024-10-02 | P3 | Alebund Pharmaceuticals | NCT07030595 AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia | ESRD (End Stage Renal Disease); Chronic Kidney Disease(CKD); Hyperphosphatemia; Hyperphosphatemia in | completed | 474 |
| 2024-10-03 | P3 | Celgene | NCT03464097 A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease | Crohn Disease | terminated | 550 |
| 2024-10-03 | P1/P2 | Kymab Limited | NCT03829501 A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) | Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer; Hepatocellular Carcinoma; Esop | terminated | 222 |
| 2024-10-03 | P3 | Corestemchemon, Inc. | NCT04745299 Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS | Amyotrophic Lateral Sclerosis | completed | 123 |
| 2024-10-03 | P3 | Mannkind Corporation MNKD | NCT04974528 Afrezza® INHALE-1 Study in Pediatrics | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | completed | 319 |
| 2024-10-03 | P3 | Kashiv BioSciences, LLC | NCT05774639 Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria | Chronic Idiopathic Urticaria | completed | 600 |
| 2024-10-04 | P1/P2 | CRISPR Therapeutics AG CRSP | NCT04035434 A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | B-cell Malignancy; Non-Hodgkin Lymphoma; B-cell Lymphoma; Adult B Cell ALL | terminated | 93 |
| 2024-10-04 | P2 | Algiax Pharmaceuticals GmbH | NCT04429919 AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain | Peripheral Post-surgical Neuropathic Pain | completed | 99 |
| 2024-10-04 | P3 | Apsen Farmaceutica S.A. | NCT04647435 Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction | Postsurgical Pain; Third Molar Extraction | completed | 396 |
| 2024-10-04 | P3 | AbbVie ABBV | NCT05439616 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5- | Autism Spectrum Disorder | completed | 161 |
| 2024-10-04 | P2 | Shanghai Pharma Biotherapeutics USA Inc. | NCT05580588 Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | Liposarcoma, Dedifferentiated | terminated | 14 |
| 2024-10-04 | P2 | GH Research Ireland Limited | NCT05800860 A Trial of GH001 in Patients With Treatment-resistant Depression | Treatment-resistant Depression | completed | 81 |
| 2024-10-04 | P3 | Laboratorios Silanes S.A. de C.V. | NCT06517823 Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain | Acute Low-back Pain | completed | 190 |
| 2024-10-05 | P2 | Ferring Pharmaceuticals | NCT05403476 A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained | Male Idiopathic Infertility | terminated | 4 |
| 2024-10-05 | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT05687071 A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | completed | 130 |
| 2024-10-05 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06703268 A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients | Type 2 Diabetes | completed | 64 |
| 2024-10-07 | P1/P2 | GlaxoSmithKline | NCT03866187 Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatit | Hepatitis B, Chronic | terminated | 236 |
| 2024-10-07 | P3 | AstraZeneca AZN | NCT04493853 Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency | Hormone-Sensitive Prostate Cancer | active not recruiting | 1012 |
| 2024-10-07 | P2 | AstraZeneca AZN | NCT04999969 Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours | Locally Advanced or Metastatic Solid Tumours | active not recruiting | 126 |
| 2024-10-07 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05435274 Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | Advanced Non-Small-Cell Lung Cancer | unknown | 380 |
| 2024-10-07 | P1/P2 | QC Kinetix LLC | NCT05742763 Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis | Osteoarthritis of the Knee; Degenerative Osteoarthritis; Knee Pain Chronic | withdrawn | |
| 2024-10-07 | P1/P2 | Aelis Farma | NCT05748405 Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome | Down Syndrome | completed | 40 |
| 2024-10-07 | P3 | Incyte Corporation INCY | NCT05755438 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Prurigo | completed | 204 |
| 2024-10-07 | P2 | Boehringer Ingelheim | NCT05865886 A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) | Cystic Fibrosis; Bronchiectasis | completed | 22 |
| 2024-10-07 | P2 | Arctic Bioscience | NCT06125808 Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study). | Psoriasis | completed | 521 |
| 2024-10-07 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT06255964 A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | Bladder Cancer | not yet recruiting | 236 |
| 2024-10-08 | P2 | Gilead Sciences GILD | NCT04958785 Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | Triple-Negative Breast Cancer | terminated | 92 |
| 2024-10-08 est. | P2 | American Regent, Inc. AIG | NCT04968379 Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia | Iron Deficiency, Anaemia | withdrawn | |
| 2024-10-08 | P2 | Spero Therapeutics SPRO | NCT05496374 A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacte | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | completed | 25 |
| 2024-10-08 | P2 | Amgen AMGN | NCT05669599 Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes M | Obesity; Overweight; Type 2 Diabetes Mellitus | completed | 592 |
| 2024-10-08 | P3 | Braintree Laboratories | NCT05890001 A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease | Non-erosive Reflux Disease; Erosive Esophagitis | completed | 400 |
| 2024-10-09 | P3 | Novartis Pharmaceuticals NVS | NCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fing | Relapsing Multiple Sclerosis | completed | 562 |
| 2024-10-09 | P3 | Eli Lilly and Company LLY | NCT05963022 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Type 2 Diabetes | completed | 206 |
| 2024-10-09 | P3 | Arcturus Therapeutics, Inc. ARCT | NCT06279871 Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults | COVID-19 | completed | 1514 |
| 2024-10-10 | P3 | Bristol-Myers Squibb BMY | NCT04908202 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Bio | Psoriatic Arthritis | active not recruiting | 670 |
| 2024-10-10 | P3 | Merck Sharp & Dohme LLC MRK | NCT05631093 A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral | HIV-1 Infection | active not recruiting | 553 |
| 2024-10-10 | P2 | Eli Lilly and Company LLY | NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | terminated | 234 |
| 2024-10-10 | P2 | Omeros Corporation OMER | NCT05972967 Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab | Paroxysmal Nocturnal Hemoglobinuria | completed | 12 |
| 2024-10-10 | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06434103 Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | Advanced Non-small Cell Lung Cancer | withdrawn | |
| 2024-10-10 | P3 | Applied Biology, Inc. | NCT06484881 Clinical Study of Probiotic Treatment for Androgenetic Alopecia | Androgenetic Alopecia; Female Pattern Baldness | withdrawn | |
| 2024-10-10 | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06509958 Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA | Postoperative Pain Management in Total Knee Arthroplasty | terminated | 15 |
| 2024-10-10 | P2 | Aquestive Therapeutics AQST | NCT06527937 Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome | Allergic Reaction | completed | 36 |
| 2024-10-11 | P3 | Actelion | NCT04175600 A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension | Hypertension, Pulmonary | active not recruiting | 138 |
| 2024-10-11 | P2 | Sanofi SNY | NCT05421598 Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma | Asthma | completed | 437 |
| 2024-10-11 | P2 | GemVax & Kael | NCT05819658 GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | completed | 78 |
| 2024-10-11 | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06739044 Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes | Type 2 Diabetes | completed | 494 |
| 2024-10-12 | P2/P3 | Applied Therapeutics, Inc. AMAT | NCT05397665 Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency | Hereditary Neuropathy Caused by SORD Deficiency | completed | 56 |
| 2024-10-13 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT05881837 A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes | Overweight or Obesity | completed | 249 |
| 2024-10-14 est. | P2 | Effector Therapeutics | NCT04622007 Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) | Non-small Cell Lung Cancer | unknown | 68 |
| 2024-10-14 | P3 | Intra-Cellular Therapies, Inc. | NCT05061719 An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Major Depressive Disorder | completed | 812 |
| 2024-10-14 | P2 | Wex Pharmaceuticals Inc. WEX | NCT05359133 A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neu | Chemotherapy-induced Neuropathic Pain; Chemotherapy-induced Peripheral Neuropathy | terminated | 35 |
| 2024-10-14 | P2 | GlaxoSmithKline | NCT05838755 A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain | Pain | terminated | 147 |
| 2024-10-14 | P2 | Travere Therapeutics, Inc. TVTX | NCT05856760 A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | Immunoglobulin A Nephropathy | completed | 48 |
| 2024-10-15 | P3 | AstraZeneca AZN | NCT04351555 A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell | Non-Small Cell Lung Cancer | active not recruiting | 358 |
| 2024-10-15 | P2 | Principia Biopharma, a Sanofi Company | NCT04520451 Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants | Immunoglobulin G4 Related Disease | completed | 27 |
| 2024-10-15 est. | P2 | CellSight Technologies, Inc. | NCT04726215 Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | Non Small Cell Lung Cancer | unknown | 50 |
| 2024-10-15 est. | P2/P3 | Paradigm Biopharmaceuticals USA (INC) | NCT04809376 Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain | Osteoarthritis, Knee | active not recruiting | 602 |
| 2024-10-15 | P1/P2 | Eisai Inc. | NCT05091346 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Melanoma; Carcinoma, Hepatocellular; Colorectal Neoplasms | completed | 89 |
| 2024-10-15 | P2/P3 | Sling Therapeutics, Inc. | NCT05276063 A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) | Thyroid Eye Disease; Graves Orbitopathy; Endocrine System Diseases; Eye Diseases; Thyroid Associated | completed | 90 |
| 2024-10-15 | P2 | PureTech PTCHF | NCT05321420 LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | active not recruiting | 240 |
| 2024-10-15 | P1/P2 | Vir Biotechnology, Inc. VIR | NCT05612581 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | Hepatitis B, Chronic | completed | 33 |
| 2024-10-15 | P1/P2 | IVIEW Therapeutics Inc. | NCT06400459 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease | Dry Eye Disease | completed | 150 |
| 2024-10-15 | P3 | Novavax NVAX | NCT06409663 A Strain Change Study for SARS-CoV-2 rS Vaccines | Severe Acute Respiratory Syndrome Coronavirus 2 Infection | completed | 60 |
| 2024-10-15 est. | P1/P2 | Frontera Therapeutics | NCT06492863 Gene Therapy(FT-003) for Wet AMD | Neovascular Age-related Macular Degeneration | recruiting | 78 |
| 2024-10-15 | P2 | Dexa Medica Group | NCT06558006 Safety and Efficacy Predimenol for Headache | Headache | completed | 60 |
| 2024-10-16 | P3 | NovoCure Ltd. NVCR | NCT03377491 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-p | Pancreas Adenocarcinoma | completed | 571 |
| 2024-10-16 | P2 | Kinevant Sciences GmbH | NCT05314517 A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | terminated | 107 |
| 2024-10-16 | P3 | Amylyx Pharmaceuticals Inc. AMLX | NCT05619783 Extension Study Evaluating The Safety And Tolerability of AMX0035 | Amyotrophic Lateral Sclerosis | completed | 352 |
| 2024-10-16 | P2 | AnaptysBio, Inc. ANAB | NCT05935085 This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD). | Atopic Dermatitis Eczema | terminated | 201 |
| 2024-10-16 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06106841 TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Mantle Cell Lymphoma | terminated | 19 |
| 2024-10-16 | P3 | Gunkang Pharmaceuticals, Inc | NCT06317350 Clinical Study to Evaluate the Efficacy and Safety of GNS-212-E in Bowel Preparation for Colonoscopy | Colonoscopy; Bowel Preparation | completed | 318 |
| 2024-10-17 | P3 | Novartis Pharmaceuticals NVS | NCT05630001 Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. | Paroxysmal Nocturnal Hemoglobinuria | completed | 52 |
| 2024-10-17 | P3 | Novartis Pharmaceuticals NVS | NCT05722522 Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | Rotator Cuff Tendinopathy | terminated | 33 |
| 2024-10-17 | P3 | Novartis Pharmaceuticals NVS | NCT05758415 Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | Rotator Cuff Tendinopathy | terminated | 60 |
| 2024-10-17 | P2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT06289166 Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor | Hemophilia | completed | 25 |
| 2024-10-17 | P2 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | NCT07190742 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patient | Chronic Hepatitis B Virus | active not recruiting | 80 |
| 2024-10-18 | P1/P2 | CARsgen Therapeutics Co., Ltd. | NCT04581473 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma | active not recruiting | 192 |
| 2024-10-18 | P3 | Boehringer Ingelheim | NCT04846881 Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) | Schizophrenia | completed | 611 |
| 2024-10-18 | P3 | Vertanical GmbH | NCT05610813 Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain | Chronic Non-specific Low Back Pain | completed | 384 |
| 2024-10-18 | P3 | GlaxoSmithKline | NCT05682326 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) | Anaemia | completed | 4 |
| 2024-10-18 | P2 | Ascendis Pharma Endocrinology Division A/S ASND | NCT05690386 A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome | Turner Syndrome | active not recruiting | 48 |
| 2024-10-18 | P2 | Kissei Pharmaceutical Co., Ltd. | NCT05831670 An Early Phase 2 Clinical Study of KSP-0243 | Colitis, Ulcerative | completed | 108 |
| 2024-10-18 | P2 | Caliway Biopharmaceuticals Co., Ltd. | NCT06005441 A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. | Subcutaneous Fat | completed | 173 |
| 2024-10-18 | P1/P2 | Chengdu Baiyu Pharmaceutical Co., Ltd. | NCT06524804 A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | Solid Tumor, Adult | terminated | 60 |
| 2024-10-18 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT06720233 Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis | Anemia | completed | 37 |
| 2024-10-20 | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04494503 Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | recruiting | 123 |
| 2024-10-20 est. | P1/P2 | Nanjing IASO Biotechnology Co., Ltd. | NCT05091541 A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Non-Hodgkin's Lymphoma | not yet recruiting | 125 |
| 2024-10-20 est. | P3 | Xeolas Pharmaceuticals Limited | NCT05602493 A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodelin | Bone Loss, Alveolar | unknown | 60 |
| 2024-10-20 | P2 | Genentech, Inc. | NCT05660850 A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | Chronic Refractory Cough (CRC) With Non-atopic Asthma; CRC With Atopic Asthma; Unexplained Chronic C | completed | 49 |
| 2024-10-21 | P2 | QED Therapeutics, a BridgeBio company | NCT04265651 Study of Infigratinib in Children With Achondroplasia | Achondroplasia | completed | 84 |
| 2024-10-21 | P2 | Otsuka Pharmaceutical Co., Ltd. | NCT05615363 A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) | Cardiac Edema (CHF) | completed | 157 |
| 2024-10-22 | P2 | Bristol-Myers Squibb BMY | NCT02060188 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Microsatellite Unstable Colorectal Cancer; Microsatellite Stable Colorectal Cancer; Mismatch Repair | completed | 385 |
| 2024-10-22 | P3 | Novartis Pharmaceuticals NVS | NCT04632927 Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment | Psoriatic Arthritis | completed | 119 |
| 2024-10-22 | P1/P2 | Incyte Corporation INCY | NCT04809467 A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Ly | Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma | terminated | 54 |
| 2024-10-22 | P3 | SBI ALApharma Canada, Inc. | NCT04815083 Fluorescence Imaging of Carcinoma During Breast Conserving Surgery | Breast Neoplasm Female; Breast Cancer | terminated | 57 |
| 2024-10-22 | P2 | Amgen AMGN | NCT04987307 Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | terminated | 221 |
| 2024-10-22 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT05079919 A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 617 |
| 2024-10-22 | P3 | Beijing Continent Pharmaceutical Co, Ltd. | NCT05115942 Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. | Liver Fibrosis | completed | 248 |
| 2024-10-22 | P3 | GlaxoSmithKline | NCT06331156 A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free | Gastroenteritis | completed | 400 |
| 2024-10-22 | P3 | Colgate Palmolive CL | NCT06607172 Clinical Efficacy of the Combined Effect of Oral Irrigator and Chemicals (0.075% CPC) | Dental Plaque; Dental Plaque Induced Gingivitis; Dental Plaque and Gingivitis; Gingivitis | completed | 30 |
| 2024-10-23 | P3 | Hoffmann-La Roche | NCT03371017 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | Triple Negative Breast Neoplasms | completed | 595 |
| 2024-10-23 | P2/P3 | LeonaBio LONA | NCT04886063 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | Alzheimer Disease | terminated | 423 |
| 2024-10-23 | P2 | Jazz Pharmaceuticals JAZZ | NCT05642442 A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease | Parkinson Disease; Tremor | completed | 169 |
| 2024-10-23 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05834543 Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | Advanced Esophageal Squamous Cell Carcinoma | terminated | 34 |
| 2024-10-23 | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT06259526 A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression | Depression | completed | 267 |
| 2024-10-23 | P2 | Glyscend, Inc. | NCT06259981 A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity | Obesity | completed | 75 |
| 2024-10-24 | P2 | Iovance Biotherapeutics, Inc. IOVA | NCT02360579 Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | Metastatic Melanoma | completed | 220 |
| 2024-10-24 | P1/P2 | Helix BioPharma Corporation HLXC | NCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Pancreas Cancer | terminated | 28 |
| 2024-10-24 | P2 | Hoffmann-La Roche | NCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHO | Lymphoma | active not recruiting | 46 |
| 2024-10-24 | P1/P2 | Palleon Pharmaceuticals, Inc. | NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) | Oncology; Melanoma; Ovarian Cancer; NSCLC; Non Small Cell Lung Cancer; Colorectal Cancer; Pancreatic | completed | 69 |
| 2024-10-24 | P2 | NeuroBo Pharmaceuticals Inc. | NCT06054815 Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH | NON-ALCOHOLIC STEATOHEPATITIS | completed | 109 |
| 2024-10-24 | P2 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06099184 Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) | Diabetic Macular Edema | completed | 27 |
| 2024-10-25 | P3 | Bristol-Myers Squibb BMY | NCT02477826 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Double | Non-Small Cell Lung Cancer | completed | 2747 |
| 2024-10-25 | P1/P2 | Hope Biosciences LLC HOPE | NCT04063215 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury a | Traumatic Brain Injury | completed | 24 |
| 2024-10-25 | P2 | Novartis Pharmaceuticals NVS | NCT04150029 A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | Acute Myeloid Leukemia | terminated | 90 |
| 2024-10-25 | P1/P2 | Accendatech USA Inc. | NCT05053880 A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | Recurrent Glioblastoma Multiforme(GBM) | active not recruiting | 48 |
| 2024-10-25 | P2 | ABLi Therapeutics, Inc. | NCT05424276 A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease | Parkinson Disease | completed | 137 |
| 2024-10-25 | P3 | Merck Sharp & Dohme LLC MRK | NCT05630755 A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emt | HIV-1 Infection | active not recruiting | 514 |
| 2024-10-25 est. | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT05741021 A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer; NSCLC; PD-1 | unknown | 84 |
| 2024-10-25 | P1/P2 | Aurion Biotech | NCT06041256 A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) | Corneal Edema; Corneal Endothelial Dysfunction | completed | 97 |
| 2024-10-27 | P2 | Novartis Pharmaceuticals NVS | NCT06097663 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart D | Coronary Heart Disease; Clonal Hematopoiesis of Indeterminate Potential (CHIP) | completed | 31 |
| 2024-10-28 | P2 | Zydus Therapeutics Inc. | NCT03617263 Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) | Non-alcoholic Fatty Liver Disease in Women With PCOS | terminated | 60 |
| 2024-10-28 | P2 | Merck Sharp & Dohme LLC MRK | NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G0 | Advanced Solid Tumors; Triple Negative Breast Cancer; Ovarian Cancer; Gastric Cancer; Colorectal Can | completed | 611 |
| 2024-10-28 | P3 | Eurofarma Laboratorios S.A. | NCT04233190 A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment | Asthma Copd | completed | 472 |
| 2024-10-28 | P3 | Insmed Incorporated INSM | NCT04594369 A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis | Non-Cystic Fibrosis Bronchiectasis | completed | 1767 |
| 2024-10-28 | P2 | AstraZeneca AZN | NCT04605549 A Study of CIN-107 in Adults With Primary Aldosteronism | Primary Aldosteronism; Hyperaldosteronism | completed | 15 |
| 2024-10-28 | P2/P3 | PT Bio Farma | NCT04741828 Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian | Vaccine | completed | 188 |
| 2024-10-28 | P3 | AstraZeneca AZN | NCT04765059 A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | active not recruiting | 98 |
| 2024-10-28 | P3 | Boehringer Ingelheim | NCT04860830 CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia | Schizophrenia | completed | 609 |
| 2024-10-28 | P3 | Janssen Research & Development, LLC | NCT04936308 Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | Arthritis, Psoriatic | completed | 453 |
| 2024-10-28 | P3 | GlaxoSmithKline | NCT04950127 Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) | Pruritus | completed | 238 |
| 2024-10-28 | P2 | Binhui Biopharmaceutical Co., Ltd. | NCT05248789 OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | Advanced Bladder Carcinoma | terminated | 4 |
| 2024-10-28 | P2 | AbbVie ABBV | NCT05513703 A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cel | Non Small Cell Lung Cancer | terminated | 9 |
| 2024-10-28 | P3 | Novo Nordisk A/S NVO | NCT05649137 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Obesity; Diabetes Mellitus, Type 2 | completed | 512 |
| 2024-10-28 | P2 | Incannex Healthcare Ltd IXHL | NCT05942911 Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | terminated | 20 |
| 2024-10-28 | P1/P2 | Clinuvel Europe Limited CUVL | NCT06388642 Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients | Erythropoietic Protoporphyria | completed | 28 |
| 2024-10-28 | P1/P2 | Norroy Bioscience Co., LTD | NCT06389695 Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients | Prostate Cancer | completed | 20 |
| 2024-10-29 | P3 | Baxalta now part of Shire | NCT02615691 A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A | Hemophilia A | completed | 120 |
| 2024-10-29 | P1/P2 | Takeda TAK | NCT04381650 A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | completed | 161 |
| 2024-10-29 | P3 | Merck Sharp & Dohme LLC MRK | NCT04662710 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adeno | Advanced/Metastatic Gastroesophageal Adenocarcinoma | completed | 895 |
| 2024-10-29 | P1/P2 | Inozyme Pharma | NCT04686175 Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic R | completed | 13 |
| 2024-10-29 | P3 | Zealand Pharma ZEAL.CO | NCT05378672 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D | Hypoglycemia; Type 1 Diabetes | completed | 8 |
| 2024-10-29 | P2 | TFF Pharmaceuticals, Inc. | NCT05501574 An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipient | Lung Transplant Rejection | terminated | 14 |
| 2024-10-29 | P3 | CSL Behring | NCT05568888 Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) | Traumatic Injury | terminated | 1366 |
| 2024-10-29 | P3 | RemeGen Co., Ltd. | NCT05673993 A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | completed | 381 |
| 2024-10-29 | P1/P2 | Cellcolabs Clinical SPV Limited | NCT06084988 A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis | Osteo Arthritis Knee | completed | 12 |
| 2024-10-29 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06475846 A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults | Preventing of Postoperative Nausea and Vomiting in Adults | completed | 235 |
| 2024-10-30 | P2 | Incyte Corporation INCY | NCT03011372 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | MPN (Myeloproliferative Neoplasms) | completed | 47 |
| 2024-10-30 | P3 | Laboratorios Sophia S.A de C.V. | NCT03193333 PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) | Primary Open-angle Glaucoma | terminated | 51 |
| 2024-10-30 | P3 | Serum Institute of India Pvt. Ltd. | NCT04351685 Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants | Mycobacterium Tuberculosis Infection | completed | 6940 |
| 2024-10-30 | P3 | Eurofarma Laboratorios S.A. | NCT04384367 Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine | Migraine | completed | 2068 |
| 2024-10-30 | P2 | Merck Sharp & Dohme LLC MRK | NCT05027074 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-20 | End-Stage Renal Disease; End-Stage Kidney Disease; Kidney Failure, Chronic | completed | 506 |
| 2024-10-30 | P2 | Archivel Farma S.L. | NCT05455112 Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis | Tuberculosis, Pulmonary | completed | 41 |
| 2024-10-30 | P3 | Nobelpharma | NCT05495425 Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC | Tuberous Sclerosis Complex | completed | 43 |
| 2024-10-30 est. | P2 | Shanghai Henlius Biotech | NCT05528406 A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation | Solid Tumor | unknown | 30 |
| 2024-10-30 | P3 | Novo Nordisk A/S NVO | NCT05567796 A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Obesity | active not recruiting | 3400 |
| 2024-10-30 | P3 | Novo Nordisk A/S NVO | NCT05646706 A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Obesity | completed | 1407 |
| 2024-10-30 est. | P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT05873803 The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps | Chronic Rhinosinusitis with Nasal Polyps | unknown | 70 |
| 2024-10-30 est. | P2 | Shanghai Ming Ju Biotechnology Co., Ltd. | NCT06149169 CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma | unknown | 10 |
| 2024-10-30 est. | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06500299 Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults | Overweight and Obesity | unknown | 180 |
| 2024-10-31 | P3 | Celgene | NCT03467958 An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease | Crohn Disease | terminated | 854 |
| 2024-10-31 | P3 | Tesaro, Inc. | NCT03602859 A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or I | Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | active not recruiting | 1400 |
| 2024-10-31 | P3 | Eyenovia Inc. | NCT03942419 Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression | Myopia | terminated | 438 |
| 2024-10-31 | P2 | Fulcrum Therapeutics FULC | NCT04004000 Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension | Facioscapulohumeral Muscular Dystrophy 1 | terminated | 14 |
| 2024-10-31 | P2 | Spruce Biosciences SPRB | NCT04544410 A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH | Congenital Adrenal Hyperplasia | terminated | 100 |
| 2024-10-31 | P2 | Regeneron Pharmaceuticals REGN | NCT04916002 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma; Triple Negative Brea | terminated | 77 |
| 2024-10-31 | P1/P2 | ESSA Pharmaceuticals | NCT05075577 EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC | Prostate Cancer | terminated | 77 |
| 2024-10-31 est. | P3 | Reistone Biopharma Company Limited | NCT05181137 A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | unknown | 368 |
| 2024-10-31 | P2 | Chipscreen Biosciences, Ltd. | NCT05336721 A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | Triple-negative Breast Cancer | terminated | 9 |
| 2024-10-31 | P1/P2 | Chimagen Biosciences, Ltd | NCT05348889 First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies | Non-Hodgkin's Lymphoma (disorder); Acute Lymphoid Leukemia, Disease (disorder) | terminated | 7 |
| 2024-10-31 | P2 | XBiotech, Inc. XBIT | NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 243 |
| 2024-10-31 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05445154 SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | 58 |
| 2024-10-31 est. | P1/P2 | Shanghai Gopherwood Biotech Co., Ltd. | NCT05505877 Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | Advanced Solid Tumor | unknown | 160 |
| 2024-10-31 | P2 | Arcturus Therapeutics, Inc. ARCT | NCT05526066 Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 | Ornithine Transcarbamylase Deficiency; OTC Deficiency; OTCD | terminated | 8 |
| 2024-10-31 | P2 | Amgen AMGN | NCT05672199 Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | terminated | 25 |
| 2024-10-31 | P2 | Vergent Bioscience, Inc. | NCT06145048 Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. | Lung Cancer; Lung Metastases | completed | 89 |
| 2024-10-31 | P3 | Lahore Medical Research Center, LLP | NCT06317064 Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea | Primary Dysmenorrhea | completed | 40 |
| 2024-10-31 est. | P2 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT06354114 A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | Advanced Breast Cancer | not yet recruiting | 80 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.